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Oncogene-induced cellular senescence (OIS) is
emerging as a potent cancer-protective response
to oncogenic events, serving to eliminate early neo-
plastic cells from the proliferative pool. Using com-
bined genetic and bioinformatic analysis, we find
that OIS is linked specifically to the activation of
an inflammatory transcriptome. Induced genes in-
cluded the pleiotropic cytokine interleukin-6 (IL-6),
which upon secretion by senescent cells acted mito-
genically in a paracrine fashion. Unexpectedly, IL-6
was also required for the execution of OIS, but in
a cell-autonomous mode. Its depletion caused the
inflammatory network to collapse and abolished se-
nescence entry and maintenance. Furthermore, we
demonstrate that the transcription factor C/EBPb co-
operates with IL-6 to amplify the activation of the in-
flammatory network, including IL-8. In human colon
adenomas, IL-8 specifically colocalized with ar-
rested, p16INK4A-positive epithelium. We propose
a model in which the context-dependent cytostatic
and promitogenic functions of specific interleukins
contribute to connect senescence with an inflamma-
tory phenotype and cancer.
INTRODUCTION
The ability of multicellular organisms to renew and regenerate
tissues contributes to longevity. However, this capacity comes
at a cost because tissue renewal sets the stage for unscheduled
proliferation upon the acquirement of oncogenic lesions (Finkel
et al., 2007). In isolation, such (epi)genetic lesions generally do
not suffice to bring about full malignancy, although small neo-
plastic cell groups may result (Mooi and Peeper, 2006). Several
mechanisms including apoptosis and lack of vessel formation
account for their failure to continue expanding and undergo fullmalignant transformation (Lowe et al., 2004; Sherr, 2004). As is
evident from the (virtual) absence of mitotic figures in many long-
standing benign tumors, proliferative arrest, too, represents an
effective mechanism suppressing continued outgrowth and the
associated risk of transformation to overt cancer.
Thecell-cyclearrestobserved innongrowingbenign lesions like
melanocytic nevi shares a number of key characteristics with cel-
lular senescence. Indeed, several lines of evidence have recently
implicated oncogene-induced cellular senescence (OIS), which is
induced prematurely (that is, before telomeric shortening can ac-
count for it [Shay and Wright, 2005]), as a vital cause of arrest of
benign neoplasms. It can be triggered by activated oncoproteins
like BRAFE600 or RASV12 or by the loss of tumor suppressor pro-
teins, like PTEN or NF1 (Chen et al., 2005; Michaloglou et al.,
2005; Courtois-Cox et al., 2006), and occurs in a variety of cell
types (Lloyd et al., 1997; Nicke et al., 2005; Denoyelle et al.,
2006). OIS is often accompanied by the upregulation of the
CDK inhibitors p15INK4B, p16INK4A, and p21CIP1, as well as by an
increase in senescence-associated b-galactosidase (SA-b-Gal)
activity (Dimri et al., 1995; Campisi, 2005). Although largely irre-
versible, upon acute inactivation of Rb or p53 genes senescence
can be reversed (Beausejour et al., 2003; Dirac and Bernards,
2003; Sage et al., 2003). A further hallmark is the formation of se-
nescence-associated heterochromatic foci (SAHF), subnuclear
structures containing heterochromatin proteins that contribute
to senescence by repressing the promoters of proliferation-asso-
ciated genes (Narita et al., 2003; Adams, 2007). OIS hasbeen cor-
related also with DNA replication stress and hyperreplication
(Bartkova et al., 2006; Di Micco et al., 2006; Mallette et al., 2007).
Compelling evidence supporting OIS as a physiologically rele-
vant mechanism limiting tumorigenesis is rapidly emerging. Se-
nescence markers have been identified in various in vivo lesions,
including human melanocytic nevi (Michaloglou et al., 2005;
Gray-Schopfer et al., 2006), murine lung adenomas (Dankort
et al., 2007), human dermal neurofibromas (Courtois-Cox et al.,
2006), human and murine prostatic adenomas (Chen et al.,
2005), murine pancreatic intraductal neoplasias (Collado et al.,
2005), murine lymphomas (Braig et al., 2005) and early murine
melanomas (Ha et al., 2007).Cell 133, 1019–1031, June 13, 2008 ª2008 Elsevier Inc. 1019
Because a picture emerges of a substantial role for OIS in the
prevention of cancer, several attempts are being made to further
resolve its mechanism. For example, function-based genome-
wide screens have unraveled unanticipated tumorigenic mecha-
nisms (Peeper et al., 2002; Berns et al., 2004; Rowland et al.,
2005). Despite such recent progress, we are only beginning to
unveil the molecular mechanism of OIS and to identify the key
players involved. By using a combination of gene expression
profiling and RNA interference, we set out to uncover previously
unidentified pathways that relay OIS.
RESULTS
OIS Is Associated with Activation of an Inflammatory
Transcriptome
To conduct an unbiased search for novel pathways mediating
OIS, we studied cellular senescence resulting from oncogenic
Figure 1. OIS Is Associated with Activation
of an Inflammatory Transcriptome Including
IL-6 Induction
(A) Cycling Tig3(et) HDF were retrovirally trans-
duced as indicated, used in a cell proliferation as-
say, and fixed and stained 11 days after infection.
(B–D) Tig3(et) cells undergoing OIS (upon trans-
duction with BRAFE600-encoding retrovirus) or by-
passing OIS (upon infection with both Cdc42V12-
and BRAFE600-encoding retroviruses) were
subjected to gene expression microarray analysis.
Quiescent cells (upon 48 hr serum starvation) were
included as controls. Exponentially cycling cells
served as a common reference.
(B) Gene Ontology (GO) analysis was applied, and
6 of 14 significantly (p < 0.01) upregulated classes
are represented in the chart (the full panel is repre-
sented in Figure S1). Significant (p < 0.01) differ-
ences in regulation of GO classes between data
sets are marked (*).
(C) Heat map of 2log-ratio (M) values of genes that
are significantly upregulated in OIS (M > 2 and p <
0.001) but not in OIS bypass or quiescence (M < 1
or p > 0.001). These filters were applied on the
complete gene expression data set, and genes
were sorted according to M values in OIS bypass.
(D) Relative IL6 transcript levels in HDF as indi-
cated were determined by qRT-PCR. Levels are
represented relative to those found in cells under-
going OIS, as mean + SD.
(E) Primary human melanocytes were lentivirally
transduced with BRAFE600, and the expression
levels of several interleukin transcripts were deter-
mined by qRT-PCR. Levels are represented rela-
tive to those found in cycling cells, as mean + SD.
(F) As in (E), but in Tig3(et) without (black bars) or
with (gray bars) sh-p16INK4A. Data are represented
as mean + SD.
signaling by BRAFE600. This common
cancer-derived mutant protein kinase
can contribute to oncogenic transforma-
tion if placed in the context of additional
genetic lesions (Davies et al., 2002; Gar-
nett and Marais, 2004). However, when introduced into human
diploid fibroblasts (HDF) in the absence of cooperating lesions,
BRAFE600 induces a robust cell-cycle arrest. This is associated
with many hallmarks of senescence, including induction of
p16INK4A (Michaloglou et al., 2005). To identify genes that are
transcriptionally upregulated during OIS and in turn decline dur-
ing OIS bypass, we performed genome-wide expression micro-
array analysis (Figure 1A; ArrayExpress accession number
E-NCMF-12).
Unbiased gene ontology (GO) analysis of the microarray data
sets revealed 14 out of 1158 GO classes to be significantly upre-
gulated during exposure to oncogenic stress (p < 0.01; Figure S1
and Table S1 available online). Compared to cells that had un-
dergone senescence, cells that bypassed OIS showed a sharp
and significant (p < 0.01) decrease in the extent of upregulation
of the ‘‘cytokine’’ and ‘‘chemokine’’ GO classes (each compris-
ing 50 genes), whereas neither category was significantly1020 Cell 133, 1019–1031, June 13, 2008 ª2008 Elsevier Inc.
upregulated in quiescence. These properties distinguished
these GO classes from all other significantly upregulated ones
(Figure 1B). Thus, OIS is specifically associated with the activa-
tion of a cytokine and chemokine response.
To deconvolute the GO classes and identify genes strongly as-
sociated with OIS, we applied the same three criteria (i.e., induc-
tion by oncogenic stress, significantly less induction during OIS
bypass, and quiescence) on the raw gene expression data set.
This yielded a collection of 24 genes, including interleukin-6
(IL-6; Figure 1C). Ingenuity pathway analysis (IPA) and gene set
enrichment analysis (GSEA) further supported the notion that
the IL-6 pathway is activated during OIS (Figure S2 and data
not shown). IL-6 is a cytokine implicated in a variety of cellular
functions, including immune response, proliferation, and tumor-
igenesis (Hirano and Kishimoto, 1989). Because IL-6 can act as
a potent inducer of growth arrest and/or differentiation (Hong
et al., 2007) and correlates with RASV12-induced senescence in
murine embryonic fibroblasts (Mason et al., 2004), we focused
our attention on this cytokine as a candidate OIS gene.
Figure 2. A Critical Role for IL-6 in Mediat-
ing OIS
(A) Cell proliferation assay of polyclonal Tig3(et)/
16i HDF expressing independent, nonoverlapping
shRNAs against IL-6 upon exposure to oncogenic
stress (transduction with BRAFE600-encoding ret-
rovirus). Cells were fixed and stained 15 days after
infection.
(B) Samples from (A) were analyzed for IL6 tran-
script levels by qRT-PCR. Levels are represented
relative to those found in control-infected cells,
as mean + SD.
(C) Samples from (A) were analyzed by western
blotting for protein expression as indicated. b-ac-
tin serves as loading control.
(D) BrdU incorporation of Tig3(et)/16i cells after
retroviral transduction with the indicated shRNAs
and labeling at 11 days after exposure to onco-
genic stress (BRAFE600 retrovirus infection). Data
are represented as mean + SD.
(E)Cell proliferation assayof senescent (BRAFE600-
expressing) Tig3(et) cells plated at equal densities
and subsequently transduced with lentivirus
expressing sh-IL-6 or sh-C/EBPb. Cells were fixed
and stained 8 days after infection.
(F) Cell proliferation assay of polyclonal Tig3(et)/16i
HDF expressing independent, nonoverlapping
shRNAs against IL-6R upon exposure to onco-
genic stress (transduction with BRAFE600-encod-
ing retrovirus). Cells were fixed and stained 15
days after infection.
(G) Samples from (F) were assessed for IL6R tran-
script levels by qRT-PCR. Levels are represented
relative to those found in control-infected cells,
as mean + SD.
Specific Upregulation of
IL-6 during OIS
We reasoned that if IL-6 mediates OIS, it
should meet three criteria. First, its ex-
pression levels must mirror OIS induction
and bypass. Indeed, quantitative RT-PCR (qRT-PCR) analysis,
while confirming the sharp induction of IL6 transcript levels ob-
served by microarray analysis, revealed a significant correlation
between IL6 expression and OIS and OIS bypass (Figure 1D).
Second, IL-6 induction by oncogenic stress must be indepen-
dent of cellular context. RNA and protein analyses of HDF and
primary human melanocytes showed that IL-6 (as well as IL-
1a, IL-1b, and IL-8) was upregulated by oncogenic signaling to
1–3 orders of magnitude, irrespective of cell type (Figures 1E,
1F, and 2C). This is consistent with previous reports on expres-
sion of interleukins, including IL-6 and IL-8, being increased in
senescent cells (Mason et al., 2004; Schnabl et al., 2003), and
these reports also indicate that this is seen for different cell types
and for oncogenes in addition to BRAFE600. Third, the induction
of IL-6 by oncogenic stress must be independent of p16INK4A.
This relates to our previous finding that although BRAFE600 in-
duces p16INK4A, BRAFE600-induced senescence in HDF occurs
independently of p16INK4A (Michaloglou et al., 2005). This crite-
rion was met, too, as we failed to detect a significant differenceCell 133, 1019–1031, June 13, 2008 ª2008 Elsevier Inc. 1021
in the levels of IL-6 upon exposure to oncogenic stress whether
p16INK4A was present or absent (Figure 1F). Thus, IL-6 is upregu-
lated specifically during OIS, independent of cell type and
p16INK4A status.
A Critical Role for IL-6 in Mediating OIS
To investigate whether IL-6 is causally involved in OIS, we de-
signed several nonoverlapping short hairpin RNAs (shRNAs) tar-
geting IL-6. Although p16INK4A is not strictly required for
BRAFE600-induced senescence in HDF, it may well contribute
to it, in the context of additional factors (Michaloglou et al.,
2005). For that reason, we generated HDF expressing a shRNA
targeting p16INK4A (‘Tig3(et)/16i’), fromwhich polyclonal cell lines
expressing distinct IL-6 shRNAswere derived. Thesewere trans-
duced with BRAFE600-encoding retrovirus, selected for proviral
integration, and plated at equal densities. A cell proliferation as-
say showed that IL-6 depletion caused cells to efficiently bypass
OIS (Figure 2A). A close correlation was observed between the
extent of IL-6 knockdown and the biological effect, arguing
against RNAi off-target effects (Figures 2A–2C). Importantly,
the OIS bypass was not due to loss of BRAFE600 expression.
To quantify the rescue from senescence, we performed
a BrdU-incorporation assay to measure the extent of DNA repli-
cation. The number of cells actively replicating DNA in the pres-
ence of oncogenic stress increased by 4-fold upon IL-6 deple-
tion (Figure 2D). To determine whether IL-6 is required not only
for induction but also for the maintenance of OIS, we transduced
senescent HDF cultures with lentivirus expressing sh-IL-6 and
monitored the cultures for proliferative activity. IL-6 depletion
led to reversal of OIS, with cells re-entering the cell cycle and re-
suming proliferation (Figure 2E; Figure S3; the results on C/EBPb
are discussed below). Thus, IL-6 is required for both induction
and maintenance of OIS. Because this experiment was per-
formed in normal HDF, this result shows also that the IL-6-de-
pendency is observed whether p16INK4A is absent or present.
Not only IL-6 but also its cognate receptor, IL-6R/GP80, was
upregulated in senescent cells, as measured by qRT-PCR
(Figure S4). To determine whether in addition to IL-6 its receptor
is also required for the mediation of OIS, we designed a set of
shRNAs targeting IL-6R. We found that IL-6R depletion caused
cells to bypass OIS, as evident by a cell proliferation assay (Fig-
ures 2F and 2G) and BrdU incorporation (Figure S5). Also in an
independent HDF strain (IMR90), IL-6 and its receptor were re-
quired for OIS induction and maintenance (Figures S6A and
S6B). We conclude that the IL-6/IL-6R pathway plays an essen-
tial role in mediating OIS.
IL-6 Inhibits Proliferation in the Context
of Oncogenic Stress
Next, we examined whether IL-6 signaling is not only required for
OIS but also sufficient to induce it by treating cell cultures with
a combination of recombinant IL-6 (rIL-6) and recombinant solu-
ble IL-6R (rsIL-6R). As a positive control, the human melanoma
cell line A375, one of the fewmelanomas that undergoes cell-cy-
cle arrest in response to IL-6 signaling, was used. Whereas acti-
vated IL-6 signaling caused A375 cells to cease proliferating, it
failed to trigger arrest in HDF (Figure 3A). Similar results were ob-
tained when we overexpressed IL6 cDNA (Figures 3B and 3C;1022 Cell 133, 1019–1031, June 13, 2008 ª2008 Elsevier Inc.note that ectopically expressed IL-6 was expressed to much
higher levels than those resulting from oncogenic signaling). In
contrast, and consistent with the IL-6-induced arrest of mela-
noma cells (harboring the BRAFE600 mutation), IL-6 markedly
augmented the ability of cells under oncogenic stress to respond
with cell-cycle arrest (Figure 3B). Thus, in the presence of onco-
genic stress, IL-6 can exert an antiproliferative effect. A mecha-
nistic explanation for this observation will be discussed in the
context of experiments shown below.
IL-6 Acts in a Cell-Autonomous Fashion in OIS
Since IL-6 acts through autocrine as well as paracrine signaling,
we next determined which pool of IL-6 is required in OIS. Onco-
genic signaling induced both intracellular and secreted IL-6 by
a factor of 10 to 30, to more than 3 ng/ml (Figure S7 and data
not shown). To examine the role of the secreted IL-6 pool, we
treated the cell culture medium with specific neutralizing anti-
bodies. mAb IL-6.8 prevents the interaction between IL-6 en
IL-6R, while mAb IL-6.16 blocks the interaction between IL-6-
IL-6R complex and gp130 (Brakenhoff et al., 1994; Kalai et al.,
1997). Preincubation of cells with IL-6.8 mAb completely abol-
ished rIL-6-induced STAT3-phosphorylation, validating the neu-
tralizing capacity of this antibody (Figure 3D). This was further il-
lustrated by the observation that even with 5 ng/ml rIL-6 added
to a 1:20 dilution of the IL-6.8 mAb-containing culture medium
of OIS cells, the total bioavailable IL-6 was effectively neutralized
(Figure 3E). Then, we performed an OIS bypass assay, with the
conditions such that the ratio of inhibitory antibody over IL-6
concentration was more than 10-fold higher than in the control
STAT3 neutralization experiment above. Whereas sh-IL-6
caused cells to bypass OIS, cells treated with either IL-6 mAb re-
mained senescent (Figure 3F). From this, we conclude that IL-6
acts in a cell-autonomous fashion to implement OIS. As this sig-
naling cascade requires also the IL-6R to be intact (Figure 2F),
these results suggest that IL-6 acts in an autocrine manner to
regulate OIS.
As a paracrine factor, secreted IL-6 contributes to tumorigen-
esis by promoting angiogenesis (Ancrile et al., 2007). To investi-
gate whether IL-6 secreted by senescent cells is endowed with
any promitogenic activity, we collected the medium from OIS
cells and transferred it to B9 hybridoma cells, which are IL-6-de-
pendent for proliferation. This led to a remarkable reversal of
their cell-cycle arrest (Figure 3G). Depletion with IL-6 antibody
completely abrogated this effect, indicating that the essential
promitogenic activity secreted by the senescent cells corre-
sponded to IL-6, which acted in a paracrine fashion. Thus,
whereas OIS requires a cell-autonomous pool of IL-6 that acts
in an autocrine fashion, this result shows that the same senes-
cent cells produce an IL-6 pool that acts promitogenically in
a paracrine fashion.
C/EBPb Is a Critical Regulator of IL-6 in OIS
Having identified IL-6 as an essential regulator of OIS, we next
wished to resolve the mechanism by which the oncogenic signal
is relayed to IL-6. In addition to IL6, many of the inflammatory
genes that were activated during OIS, including IL1B and IL8
(Figures 1E and 1F), are regulated by the transcription factor
C/EBPb. Because the IL-6promoter contains a perfect consensus
Figure 3. IL-6 Inhibits Proliferation in the
Context of Oncogenic Stress and Acts in
a Cell-Autonomous Fashion in OIS
(A) Cell proliferation assays of A375 human mela-
noma cells and Tig3(et)/16i HDF treated with re-
combinant IL-6 (rIL-6) and recombinant soluble
IL-6R (rsIL-6R), fixed, and stained after 4 days.
(B) The proliferative potential of polyclonal
Tig3(et)/16i HDF expressing IL-6 (HA-tagged or
untagged, as indicated) was determined in a cell
proliferation assay in the presence and absence
of oncogenic stress (transduction with BRAFE600
retrovirus).
(C) Samples from (B) were assessed by western
blotting for protein expression as indicated.
b-actin serves as loading control.
(D) HepG2 cells were treated with rIL-6, in the
presence or absence of IL-6.8 mAb, and the
expression levels of phosphorylated STAT3
(p-STAT3) and total STAT3 (t-STAT3) were deter-
mined by western blotting.
(E) Left: Quantification of the amount of bio-avail-
able IL-6 in Figure 3F employing the B9 (hybrid-
oma growth factor) assay. Right: Same quantifica-
tion after dilution of the IL-6.8 antibody and
addition of different amounts (‘‘x’’) of rIL-6.
B.D.L., below detection limit.
(F) Left: Cell proliferation assay of oncogenically
stressed (BRAFE600-expressing) Tig3(et)/16i HDF
treated with either of two neutralizing IL-6 mAbs
(6.8 and 6.16) or control antibody. Right: Cells
that bypassed OIS owing to shRNA-mediated
IL-6 depletion serve as controls.
(G) 3H-thymidine-incorporation proliferation assay
in B9 hybridoma cells on medium collected from
OIS cells in the absence or presence of the IL-
6.8 antibody, compared to no treatment. Data
are represented as mean + SD.binding site for this transcription factor (Figure 4A), we asked
whether C/EBPb is critically involved in the regulation of these
interleukins, and in OIS. First, we determined whether it is acti-
vated as a function of oncogenic stress. Indeed, several
C/EBPb isoforms (including LIP and LAP, which are generated
by differential start site usage and proteolytic cleavage [Ramji
and Foka, 2002]), were upregulated during OIS (Figure 4B).
This was accompanied by an almost 10-fold elevation of CEBPB
mRNA, as determined by qRT-PCR (see below), suggesting that
this reflects the primary mode of activation in this setting.
Consistently, C/EBPb DNA-binding capacity was increased
(Figure 4C, Figure S8). To confirm this interaction in living cells,
chromatin immune precipitation (ChIP) was performed. As as-
sayed with two independent C/EBPb antibodies, we observed
that C/EBPb bound to the IL6 promoter in vivo upon exposure
of cells to oncogenic stress (Figure 4D). Depletion of C/EBPb
strongly diminished this binding, further validating the specificity
of the signal. Thus, during OIS, C/EBPb is recruited to the IL6
promoter in vivo.
These results raised the possibility that C/EBPb has an essen-
tial role in OIS. Indeed, shRNAs that successfully targetedC/EBPb (Figure 4E) led to continued cell proliferation in the
face of oncogenic stress (Figure 4F). In an independent experi-
ment, OIS bypass by C/EBPb depletion was quantified by
BrdU incorporation (Figure S5). Similar to IL-6, C/EBPb was re-
quired also for maintenance of OIS (Figure 2E). The induction of
IL-6 by oncogenic stress and the recruitment of C/EBPb to the
IL6 promoter argued that C/EBPb mediates OIS by conveying
the oncogenic signal to the IL6 promoter. This was confirmed
by the steep drop in the transcript and protein levels of IL-6
upon depletion of C/EBPb (Figures 4G and 4H). As discussed
for Figure 1, oncogenic stress elicited the activation of multiple
interleukins, including IL-8. Expression of this latter cytokine,
which mainly functions as a chemoattractant for neutrophils at
sites of inflammation, is also regulated by C/EBPb. Therefore,
we examined whether IL-8, too, is expressed during OIS as
a function of C/EBPb. Indeed, C/EBPb depletion caused IL8
mRNA to decline to background levels (Figure 4G). These find-
ings extend a previous observation that C/EBPb is involved in
RASV12-induced senescence in murine cells (Sebastian et al.,
2005). Although not precluding an involvement of other signaling
pathways, these results demonstrate that C/EBPb is a criticalCell 133, 1019–1031, June 13, 2008 ª2008 Elsevier Inc. 1023
Figure 4. C/EBPb Is a Critical Regulator of
IL-6 in OIS
(A) Schematic representation of several transcrip-
tion factor binding sites in the IL6 promoter (not all
sites are indicated).
(B) C/EBPb protein expression of cycling and OIS
Tig3(et)/16i HDF, as determined by western blot-
ting. b-actin serves as loading control.
(C) Electrophoretic mobility shift assay (EMSA) on
nuclear lysates from cycling and OIS cells with the
C/EBPb-binding site of the IL6 promoter as a ra-
diolabeled probe. Unlabeled wild-type andmutant
probe competitions (250-fold excess) and anti-
body treatment were used to determine the spec-
ificity of the assay.
(D) Chromatin immunoprecipitation (ChIP) deter-
mining the in vivo binding of C/EBPb to the IL6 pro-
moter upon exposure to oncogenic stress
(BRAFE600 retroviral infection). To determine spec-
ificity, we used two independent C/EBPb anti-
bodies (1, Cell Signaling, and 2, GeneTex), along
with a control (anti-TrkB) antibody, on chromatin
isolated from cycling and OIS cells. OIS cells ex-
pressing sh-C/EBPb were included as an extra
control for the specificity of C/EBPb antibodies.
Relative IL6 promoter binding was plotted as
mean + SD.
(E–H) Polyclonal Tig3(et)/16i cell lines expressing
independent, nonoverlapping shRNAs for C/EBPb
were subjected to oncogenic stress (infection with
BRAFE600 retrovirus).
(E) C/EBPb and BRAF protein levels, as deter-
mined by western blotting. b-actin serves as load-
ing control.
(F) Cell proliferation assay of polyclonal Tig3(et)/
16i HDF expressing independent shRNAs against
C/EBPb. Cells were fixed and stained 15 days after
infection.
(G) Samples from (F) were assessed for CEBPB,
IL6, and IL8 transcript levels by qRT-PCR. Levels
are represented relative to those found in con-
trol-infected cells, as mean + SD.
(H) BRAF, C/EBPb, and IL-6 protein levels, as de-
termined by western blotting. b-actin serves as
loading control.mediator in an interleukin pathway leading to OIS of human
fibroblasts.
IL-6 Depletion Correlates with Reduced Formation of
SAHF and Deregulation of p15INK4B Expression
Senescent cells often accumulate SAHF. These subnuclear
structures contain heterochromatin proteins and are produced
upon cellular exposure to stress. To examine whether IL-6-de-
pendent OIS correlates with SAHF formation, we performed
fluorescence stainings for K9M-H3 and DNA. In parallel, we
performed a cell proliferation assay to monitor the induction
and bypass of OIS. As expected, cells exposed to oncogenic
stress accumulated SAHF, along with K9M-H3 modification
(Figure 5A). In contrast, OIS bypass upon IL-6 depletion was as-
sociated with a marked decline in the number of cells containing
SAHF. Consistent with its role in OIS, similar observations were
made for C/EBPb. These results reveal a correlation between1024 Cell 133, 1019–1031, June 13, 2008 ª2008 Elsevier Inc.IL-6 and SAHF formation. Although further study will be required
to determine their exact relationship, a role for IL-6 in the regula-
tion of chromatin is not unprecedented (Hodge et al., 2001).
To begin probing for connections between interleukin signal-
ing and the cell-cycle machinery, we determined the expression
of several cell-cycle genes, including all four INK4 genes (encod-
ing p15INK4B, p16INK4A, p18INK4C, and p19INK4D). Whereas
p16INK4A was moderately induced by oncogenic stress,
p15INK4B was upregulated more than 20-fold (Figures 5B and
5C). Unexpectedly, the induction of p15INK4B was markedly sup-
pressed by depletion of IL-6 (Figures 5D and 5E). Adding to the
significance of this finding, depletion of C/EBPb also diminished
the induction of p15INK4B by oncogenic stress (Figures 5F and
5G). This was specific for p15INK4B and not a general effect on
the cell-cycle machinery, as it was not observed for p16INK4A.
Because C/EBPb binds to the CDKN2B promoter in response
to cytokine stimulation (Gomis et al., 2006), their communication
is likely to be direct. Conversely, ectopic expression of C/EBPb
was sufficient to bring about cell-cycle arrest (Figures 5H and
5I), extending previous data in murine cells (Sebastian et al.,
2005). This was associated with a concomitant induction of
p15INK4B and IL-6, showing that this transcription factor is also
sufficient to activate the cytostatic IL-6-p15INK4B axis (Figures
5J and 5K). These data demonstrate that p15INK4B is regulated
by oncogenic stress, in a significant part in a C/EBPb-IL-6-
dependent manner.
Although p15INK4B, when expressed at high levels, induced
cell-cycle arrest (data not shown), lower levels acted only weakly
cytostatically (Figure S9). Whereas IL-6 was insufficient to inhibit
proliferation in the absence of oncogenic stress (Figures 3A and
3B), in the context of p15INK4B it elicited a strong cytostatic effect
(Figure S9). It thus appears that BRAFE600 triggers activation
of p15INK4B, IL-6, and IL-6R, which act in concert to impose
cell-cycle arrest.
IL-6 Is a Central Regulator of an Inflammatory
Network Mediating OIS
To investigate themechanism bywhich IL-6 acts as a critical me-
diator of OIS, we investigated its effects on the transcriptome.
We performed microarray expression analysis on cells exposed
to oncogenic stress, in the absence or presence of IL-6 shRNA
(Figure 6A; ArrayExpress accession number E-NCMF-13). Unbi-
ased analysis of transcriptional changes in GO classes revealed
a distinct pattern for the inflammatory network. Compared to
cells that had undergone OIS, cells that bypassed OIS owing
to depletion of IL-6 showed a strong suppression of the inflam-
matory response (Figure 6B, 6C; Figure S10, and Table S2).
Strikingly, this pattern was very similar to that of cells that had
not been exposed to oncogenic stress at all, as well as of cells
that had bypassed OIS because of the silencing of C/EBPb.
This effect was specific, as we failed to observe it for other GO
classes such as ‘‘receptor’’ and ‘‘cytosolic [Ca2+] elevation.’’
Thus, IL-6 fulfils a central role in keeping the genetic inflamma-
tory network in an active state: Upon IL-6 depletion, the network
collapses and cells bypass OIS.
To validate these results, we quantified the transcript levels for
interleukins that fell into the significant outlier GO classes related
to inflammation. This confirmed our microarray results and dem-
onstrated that all of these cytokines are activated by oncogenic
stress in an IL-6-dependent manner (Figure 6D). Remarkably,
IL-6 depletion caused a marked decrease in the levels of
C/EBPb, too (Figure 6D). This would argue that there is a two-
way communication between IL-6 and C/EBPb, possibly a posi-
tive feedback loop, with IL-6 acting as a positively acting factor
to maintain or activate the loop and C/EBPb corresponding to
the transcription factor directly regulating target genes. This pre-
dicts that C/EBPb and IL-6 control a large set of overlapping
genes within the inflammatory transcriptome, which was in fact
already suggested by the heat map in Figure 6C. However, be-
cause this heat map was limited to genes that are significantly
regulated, we also tested this hypothesis in an unbiasedmanner.
Complete data sets for C/EBPb- or IL-6-depleted cells were
compared in a two-sample correlation plot. This confirmed that
there is a highly significant overlap of genes regulated by each
C/EBPb and IL-6: 1084 genes were coregulated by C/EBPband IL-6, and only three genes were antiregulated (Figure 6E).
These results argue that the mechanism by which IL-6 controls
the cellular response to oncogenic signaling involves a positive
feedback loop with C/EBPb, which acts to sustain and amplify
the activation of the inflammatory network.
IL-8 Plays a Role in OIS
This model raises the question whether the role of IL-6 is unique
amongseveral other interleukinsbeingactivated in response toon-
cogenic stress.These include IL-8,whoseexpression levels riseup
1000-fold in response to oncogenic signaling (Figures 1E and 1F),
in a strictly IL-6-dependent manner (Figure 6D). We reasoned that
the observed effect of IL-6 on IL-8 expression points to an involve-
ment of the C/EBPb transcription factor, for which we thus investi-
gated a possible relationship with IL-8. ChIP analysis revealed that
C/EBPb was recruited to the IL8 promoter in response to
oncogenic stress, just like it is recruited to the IL6 promoter
(Figure 6F). Because C/EBPb and IL-6 apparently act in a positive
feedback loop, thisobservation further connects these interleukins
during oncogenic signaling. To examine any biologically relevant
role of IL-8 in this setting, we generated specific shRNAs and de-
termined whether they interfere with OIS. Similar to what we had
observed for IL-6, knockdown of IL-8 led to efficient OIS bypass
(Figure 6G, Figure S11). Thus, the critical role of IL-6 in OIS is
shared by IL-8, which is expressed as a function of IL-6.
IL-8 Colocalizes with p16INK4A in Growth-Arrested,
Human Colon Adenoma Cells
To find in vivo correlates of our observations made in vitro, we
analyzed the expression of IL-8 in human colon adenomas. We
choose this lesion because it contains cell groups displaying
two hallmarks of cellular senescence, strong p16INK4A immuno-
positivity and absence of both mitotic figures and Ki-67 positiv-
ity, as previously reported (Dai et al., 2000). These cell groups al-
ternate with stretches of p16INK4A-negative ones containing
many Ki-67-positive cells. Of 20 adenomas tested, 19 contained
areas and stretches of cells with distinct IL-8 positivity, associ-
ated with absence of Ki-67-positive nuclei, indicating prolifera-
tive arrest (Figure 7A). These arrested cell stretches stood out
against adjacent areas of proliferating, IL-8-negative adenoma.
In 18 out of these 19 samples, stretches of p16INK4A positivity
largely overlapped with the nonproliferating, IL-8-positive ade-
noma areas. Occasionally, focal IL-8 positivity was observed
also in arrested cell groups that were negative for p16INK4A stain-
ing (Figure S12). Compared to p16INK4A immunopositivity,
variations in IL-8 positivity were generally more gradual, with
the highest intensity observed in the areas with absent or very
fewKi-67-positive nuclei. These results support amodel in which
interleukins contribute to OIS in vivo.
DISCUSSION
Although accumulating evidence suggests that OIS constitutes
a vital protective system restricting the expansion of incipient
neoplastic cells, its mechanism is not well understood. By ex-
pression profiling, we found that 1% of all GO classes were
upregulated upon exposure of cells to oncogenic signaling
(BRAFE600). However, only two classes, ‘‘cytokine’’ andCell 133, 1019–1031, June 13, 2008 ª2008 Elsevier Inc. 1025
Figure 5. IL-6 Depletion Correlates with Reduced Formation of SAHF and with Deregulation of p15INK4B Expression
(A) Confocal microscopy images of cycling and polyclonal Tig3(et)/16i cell lines expressing sh-IL-6 or sh-C/EBPb upon exposure to oncogenic stress (BRAFE600
retroviral transduction). Immunofluorescence was performed for K9M-H3 (green in the overlay), and DAPI staining (red in the overlay) was used to visualize DNA.
Percentages of SAHF-positive cells are indicated. In parallel, a cell proliferation assay was performed (top).
(B) Induction of INK4-family transcript levels in OIS Tig3(et) cells relative to cycling cells, as determined by qRT-PCR and represented as mean + SD.
(C) Samples from (B) were analyzed by western blotting for BRAF, p15INK4B, and p16INK4A protein expression as indicated. b-actin serves as loading control.
(D) p15INK4B and BRAF protein levels as a function of IL-6 depletion, as determined by western blotting. b-actin serves as loading control.
(E) CDKN2B RNA levels as a function of IL-6 depletion, as determined by qRT-PCR. Data are represented as mean + SD.
(F) Determination by western blotting of protein levels as indicated, as a function of C/EBPb depletion. b-actin serves as loading control.
(G) CDKN2B RNA levels as a function of C/EBPb depletion, as determined by qRT-PCR. Data are represented as mean + SD.
(H) Cell proliferation assay for control and C/EBPb-overexpressing IMR90(et)/16i cells. Cells were fixed and stained 10 days after infection.
(I) BrdU-incorporation of samples in (H). Cells were labeled 8 days after infection with C/EBPb-encoding retrovirus. A representative experiment out of three
independent experiments is shown.1026 Cell 133, 1019–1031, June 13, 2008 ª2008 Elsevier Inc.
‘‘chemokine,’’ in turn declined during OIS bypass. RNAi experi-
ments revealed a causal relationship between the induction of
some of these cytokines, in particular IL-6 and IL-8, and the abil-
ity of cells to undergo OIS. IL-6 is a pleiotropic cytokine that can
function as an autocrine or paracrine tumorigenic factor. We
show that senescent cells can act as the source of such a prom-
itogenic IL-6 pool. We also find that in OIS, unexpectedly, IL-6 is
required in a cell-autonomous manner to implement cell-cycle
arrest. Because OIS apparently requires an intact IL-6R, too,
our results suggest that IL-6 acts in an autocrine and cell-auton-
omous fashion to implement OIS. Similar results are reported in
an accompanying paper by Gil and colleagues (Acosta et al.,
2008), showing that CXCR2-binding chemokines expressed by
senescent cells regulate growth arrest.
In response to oncogenic stress, both IL6 and IL8 genes were
activatedby the transcription factorC/EBPb, upon its recruitment
to either promoter. C/EBPb depletion caused cells to bypassOIS
effectively, which correlated with the loss of expression of both
interleukins. Because, conversely, IL-6 depletion was followed
by a strong decline in the levels of both C/EBPb and IL-8, our
results suggest that C/EBPb and IL-6 constitute a positive feed-
back network regulating OIS. In parallel to these observations in
vitro, we observed a correlation between increased IL-8 expres-
sion and p16INK4A immunopositivity in growth-arrested cells in
human colorectal adenomas. This supports a model in which
activation of the cytokine network contributes to OIS in vivo.
Oncogenic stress triggered also the induction of the CDK inhibi-
tor p15INK4B, which was dependent on the presence of both IL-6
andC/EBPb. Assuch, this result establishesa linkbetweenOIS-ac-
tivated interleukin signaling and the cell-cycle machinery. Our re-
sults suggest that IL-6 acts in concert with its receptor and
p15INK4B to causecell-cycle arrest in response tooncogenic stress.
Althoughnotstrictly required forfibroblastOIS, it isconceivable that
p16INK4A, if induced, contributes as well. Such amodel would be in
linewith the recent finding that in the absence of p16INK4A, p15INK4B
acts as a critical tumor suppressor (Krimpenfort et al., 2007).
A cytostatic role for IL-6 in specific contexts is consistent with
a large body of observations (Hong et al., 2007). We consider it
unlikely that the IL-6 (or IL-8) pools required for OIS (this paper),
and for promoting oncogenicity (Sparmann and Bar-Sagi, 2004;
Ancrile et al., 2007) or cell proliferation (this paper) are inherently
different. Instead, we suggest that the geneticmakeup of the IL-6
target cell, whether normal or transformed, contributes to spec-
ifying the biological response to IL-6. In keeping with this, IL-6 in-
hibits proliferation of early- but not advanced-stage melanoma
cells (Lu and Kerbel, 1993). This duality is reminiscent of that of
another cytokine, transforming growth factor b (TGF-b), which
restrains the proliferation of nonmalignant cells but upon overex-
pression in tumor cells fosters expansion and metastasis. This
parallel between IL-6 and TGF-b extends further, as defects in
signaling by the latter cytokine, too, allow cells to overcome
OIS, which is associated with suppression of p15INK4B (Tremain
et al., 2000). Furthermore, two other secreted factors, PAI-1 and
WNT-2, have been implicated in senescence (Kortlever et al.,
2006; Ye et al., 2007). The expression of PAI-1 is under controlof IL-6, as well as of C/EBPa, raising the interesting possibility
that IL-6, C/EBP transcription factors, and the urokinase-depen-
dent plasminogen activation system together constitute a stro-
mal signaling network regulating cellular senescence.
An important role for the stroma is highlighted also by the
property of senescent fibroblasts to secrete high levels of metal-
loproteinases, growth factors, and inflammatory cytokines
(Campisi, 2005; this paper). In fact, this might reflect a counter-
productive side effect of the organism’s ability to limit the pool
of incipient cancer cells by activating OIS. Indeed, senescent
fibroblasts resemble those associated with cancer as well as
wound healing (Campisi, 2005). Factors that are secreted by
senescent fibroblasts can promote cell proliferation and tumori-
genesis (Krtolica et al., 2001; this paper). A connection between
senescence and inflammation is supported further by a recent
hepatocellular carcinoma model, in which p53 reactivation led
to senescence and subsequent elimination of the tumor medi-
ated by the induction of a set of inflammatory cytokines (Xue
et al., 2007). Interestingly, IL-6 levels increase also with aging
(Hong et al., 2007). As our study implicates specific interleukins
in cell-autonomous regulation of senescence, as well as in stim-
ulation of proliferation, they arguably are endowed with the ca-
pacity to link senescence with aging, inflammation, and cancer.
EXPERIMENTAL PROCEDURES
Cell Culture, Viral Transduction, Cell Proliferation Assay,
and Cell-Cycle Analysis
The human diploid fibroblast cell line Tig3 expressing the ecotropic receptor
and hTERT (‘‘Tig3(et)’’), its sh-p16INK4A-expressing derivative ‘‘Tig3(et)/16i,’’
and human A375 melanoma cells were maintained in DMEM (GIBCO) supple-
mented with 9% fetal bovine serum (Greiner Bio-One), 2 mM glutamine, 100
units ml1 penicillin, and 0.1 mg ml1 streptomycin (all GIBCO). The human
diploid fibroblast cell line IMR90 expressing the ecotropic receptor, shRNA
for p16INK4A, and hTERT (‘‘IMR90(et)/16i’’) were maintained in MEM + Earle’s
salts (GIBCO) containing all supplements mentioned above and nonessential
amino acids, 0.15% sodium bicarbonate, and 1 mM sodium pyruvate (all
GIBCO). Normal human melanocytes were isolated, maintained, and lentivir-
ally transduced as described (Michaloglou et al., 2005).
Retroviral transductions were performed with Phoenix cells as producers
of viral supernatants as described (http://www.stanford.edu/group/nolan/
retroviral_systems/phx.html). For cell proliferation assays, cells were typically
infected with shRNA-encoding virus, briefly selected for successful proviral in-
tegration, and subsequently infected with BRAFE600-encoding virus. Then, 43
105 cells were seeded into 6-well plates and fixed and stained 11–15 days
postinfection with crystal violet or Coomassie Blue. BrdU analysis, STAT3-
phosphorylation assay, andmeasurement of bioavailable IL-6 were performed
as described in the Supplemental Experimental Procedures.
Plasmids
pMSCV-blast-BRAFE600, pBABE-puro-BRAFE600, pBABE-bleo-IL-6, pBABE-
bleo-30HA-IL-6, pLZRS-IRES-zeo-Cdc42V12, and pBABE-puro-C/EBPb
(expressing the full-length cDNA with mutated [ATG/ TTG] alternative start
sites) were used for retroviral transduction. Sequences of shRNAs are de-
scribed in the Supplemental Experimental Procedures.
Microarray Gene Expression Profiling
Total RNA from at least two independent experiments was isolated, purified,
and amplified. Amplified RNA (aRNA) was subsequently labeled either with(J) Protein levels of samples in (H), as determined by western blotting. b-actin serves as loading control.
(K) IL6 transcript levels of samples in (H), as determined by qRT-PCR . Levels are represented relative to those found in control-infected cells, as mean + SD.Cell 133, 1019–1031, June 13, 2008 ª2008 Elsevier Inc. 1027
Figure 6. IL-6 Is a Central Regulator of an Inflammatory Network Mediating OIS
(A–E) Polyclonal Tig3(et)/16i cell lines expressing either sh-IL-6 or sh-C/EBPbwere exposed to oncogenic stress (BRAFE600 retroviral transduction) and compared
to cycling cells for their gene expression profiles. OIS cells serve as common reference.
(A) Cell proliferation assay and experimental outline.
(B) Microarray gene expression data were analyzed for regulation of GO classes. Six of 18 significantly (p < 0.01) downregulated classes are represented in the
chart (the full panel of classes is represented in Figure S10).
(C) Heat map of M values of genes that are significantly (2 > M > 2 and p < 0.001) regulated in cycling cells and cells that bypass OIS because of depletion of
C/EBPb or IL-6, with OIS as a general reference. Filters were applied on the complete gene expression data set, and genes were sorted according to M value
in cycling cells.
(D) The levels of several interleukin transcripts were determined by qRT-PCR in cycling, OIS, and OIS bypass cells, as indicated. Data are represented as
mean + SD.1028 Cell 133, 1019–1031, June 13, 2008 ª2008 Elsevier Inc.
Cy5 or Cy3. Labeled aRNA was hybridized to oligo arrays (Operon v3 library),
and a dye-swap was performed for each experimental sample.
Gene ontology analysis is described in the Supplemental Experimental
Procedures.
qRT-PCR
Total RNA was DNase treated with RQ1 RNase-Free DNase (Promega). Re-
verse transcription was performed with Superscript II first strand kit (Invitro-
(E) Two-sample correlation plot of oncogenically stressed cells depleted for either C/EBPb or IL-6. The Pearson product-moment coefficient, reflecting the
degree of linear relationship between two variables, was calculated as a measure of coregulation of the data sets; p value represents the probability that the
correlation coefficient is 0 (null hypothesis).
(F) ChIP determining the in vivo binding of C/EBPb to the IL8 promoter upon exposure to oncogenic stress (BRAFE600 retroviral infection). OIS Tig3(et)16i cells
expressing sh-C/EBPb were included as an extra control for the specificity of the C/EBPb antibody. Relative IL8 promoter binding was plotted as mean + SD.
(G) Cell proliferation assay of polyclonal Tig3(et)/16i HDF expressing independent shRNAs against IL-8 upon exposure to oncogenic stress (transduction with
BRAFE600-encoding retrovirus). Cells were fixed and stained 15 days after infection. (For concomitant quantification of IL8 transcript levels, see Figure S11.)
Figure 7. A Role for Interleukins In Vivo and
a Model Reconciling the Antagonistic Func-
tions of Interleukins in OIS and Cancer
(A) Consecutive 3-mm-thick paraffin sections of 20
FFPE human colon adenomas, ranging in size
from 5 to 25 mm, were immunostained for IL-8,
the proliferation marker Ki-67, and p16INK4A. Three
representative examples are shown (magnification
upper two panels, 2003; lower panel, 1003). In
addition to common overlapping immunopositivity
for p16INK4A and IL-8 in arrested colon adenoma
cells, some IL-8 positivity was detected in the dis-
tal part of normal colorectal crypts and in the sur-
face epithelium but not in the basal parts of crypts
(data not shown).
(B) Our results suggest a model in which a primary
response to oncogenic stress corresponds to the
establishment of a genetic inflammatory signa-
ture, in a C/EBPb-dependent fashion. Effector
genes include a set of interleukins, such as IL6,
which operates in a positive feedback loop
with C/EBPb (orange circle), as well as CDKN2B
(encoding p15INK4B). Autocrine IL-6 signaling is
essential for the cellular response to oncogenic
stress; in its absence, cells fail to undergo OIS
and continue proliferating. Although paracrine
IL-6 signaling may also contribute to this, it is
not essential. In a paracrine fashion, IL-6 can pro-
mote proliferation of susceptible (cancer) cells.
Thus, depending on the context, specific interleu-
kins elicit anti- (red) or proproliferative (green) ef-
fects, thereby affecting senescence and cancer.
gen). qRT-PCR was performed with the SYBR
Green PCR Master Mix (Applied Biosystems) on
an ABI PRISM 7700 Sequence Detection System.
Primer sequences are described in the Supple-
mental Experimental Procedures.
Control primers were RPL13 andHPRT1. Except
for C/EBPb, all primer pairs span exon-exon bar-
riers. Data are represented as mean + SD of three
independent experiments.
Antibodies
Antibodies used for western blotting were against b-
actin (AC-74; A5316; Sigma), BRAF (sc-5284; Santa
Cruz), C/EBPb (sc-150; Santa Cruz), IL-6 (AF-206-
NA; R&D Systems), p15INK4B (sc-612; Santa Cruz), p16INK4A (JC8;MS-889; Neo-
Markers), STAT3 (sc-482; Santa Cruz), and phospho-Tyr705-STAT3 (3E2; #9138;
Cell Signaling). The antibodies used for immunofluorescence were against tri-
methyl-Lys9-histone H3 (07-442; Upstate) and IL-6 (AF-206-NA; R&D Systems).
Electrophoretic Mobility Shift Assay
A standard method was used for electrophoretic mobility shift assay (EMSA).
Except for the consensus C/EBPb binding site, probes correspond to theCell 133, 1019–1031, June 13, 2008 ª2008 Elsevier Inc. 1029
nt 173 to nt 138 region within the human IL6 promoter, spanning the CRE
andC/EBPb binding sites. To test specificity, probes were usedwithmutations
in these binding sites. Probes and labeling technique are described in the Sup-
plemental Experimental Procedures.
For competition binding assays, unlabeled probes were added to the reac-
tion in 2503molar excess. For antibody treatment, nuclear extracts were pre-
incubated with 2 mg C/EBPb antibody (C-19; sc-150; Santa Cruz).
Chromatin Immunoprecipitation
ChIP was performed as described (Rowland et al., 2005) with the following
modifications. Precleared chromatin was incubated with 2 mg control (TrkB:
Santa Cruz sc-8316) or specific antibody (C/EBPb: Cell Signaling #3087, Santa
Cruz sc-150, or GeneTex MS-NFIL21-PX1); qPCR was performed with the Abi
Prism 7700 Sequence Detection System and SYBR Green PCR Master Mix
(Applied Biosystems). Primer sequences are described in the Supplemental
Experimental Procedures. Relative promoter binding is represented as the ra-
tio between the amount of specific and nonspecific amplified DNA fragments
as mean + SD of three independent experiments.
Immunohistochemistry
Twenty formalin-fixed paraffin-embedded human colorectal tubular adeno-
mas were immunostained for p16INK4A and proliferation marker Ki-67 (with
MIB-1 antibody), as previously described (Michaloglou et al., 2005). Staining
for IL-8 was performed with routine procedures; the antibody was fromBender
MedSystems (BMS136; NAP II).
ACCESSION NUMBERS
The microarray data have been deposited in the ArrayExpress repository un-
der accession numbers E-NCMF-12 and E-NCMF-13.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, twelve figures, and two tables and can be found with
this article online at http://www.cell.com/cgi/content/full/133/6/1019/DC1/.
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